Glenn Killingworth has been appointed director of business development at CiVentiChem, as part of the company’s recent expansion efforts at its U.S. headquarters in NC and pilot and production facility in Hyderabad, India.

Mr. Killingworth will apply his experience to the launch of the company’s new assets in Hyderabad and cGMP kilo-lab synthesis capabilities in Cary, NC. Mr. Killingworth has more than 20 years of experience in sales, marketing, collaborative ventures and business development in both Europe and the U.S., along with a strong scientific background in the field of pharmaceutical and chemistry R&D.

He joins the company from WuXi AppTec, where he served as director of key accounts responsible for the development of European-centric global pharmaceutical companies. Previously, he served on the operational board at Peakdale Molecular. Also, he worked with both European and U.S.-based companies during his tenure at Almac Sciences. Previously he was business development manager at Fisher Scientific UK.

“Glenn has built a proven track record of commercial success through sales development, strategic marketing and novel collaborative ventures,” said Bhaskar Venepalli, president of CiVentiChem. “We are delighted to have Glenn on board at a very critical juncture of our growth plans and our drive to expand our market share with the investments we recently made in North Carolina as well as in Hyderabad, India” said Venepalli.